• In June 2026, a key FDA advisory committee unanimously recommended approval of Moderna’s mRNA-based influenza vaccine, mFlusiva (mRNA-1010), for adults aged 50 and older after late-stage data showed it was about 27% more effective than a standard flu shot.
• This vote not only advances what could become the first mRNA flu vaccine but also reinforces confidence in Moderna’s broader shift beyond COVID-19 into respiratory, oncology, and rare-disease applications of its mRNA platform.
• We’ll now examine how the FDA panel’s support for mFlusiva could influence Moderna’s investment narrative and future pipeline expectations.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Moderna Investment Narrative Recap

To own Moderna today, you need to believe its mRNA platform can move beyond a shrinking COVID-19 franchise into a broader, sustainable portfolio in respiratory, oncology, and rare diseases. The FDA panel’s unanimous support for mFlusiva reduces regulatory uncertainty around a key near term flu catalyst, but it does not eliminate the biggest current risk: whether new vaccines can actually replace volatile COVID-19 revenues fast enough to narrow large ongoing losses.

The most relevant recent development alongside the mFlusiva vote is Moderna’s June Science Day update, where management mapped out “Horizon 2 and 3” programs across infectious disease, cancer, and rare disorders. That event underlined how flu, RSV, and combination vaccines sit at the front of a much larger pipeline, so the advisory committee’s positive stance on mFlusiva could shape confidence in future readouts and approvals across this broader set of candidates.

Yet even with encouraging flu data, investors should still pay close attention to the risk that new launches fail to offset ongoing COVID-19 revenue volatility and...

Moderna's narrative projects $3.7 billion revenue and $695.7 million earnings by 2029. This requires 18.2% yearly revenue growth and an earnings increase of about $3.9 billion from -$3.2 billion today.

Uncover how Moderna's forecasts yield a $44.25 fair value, a 37% downside to its current price.

Exploring Other Perspectives

Before this flu decision, the most pessimistic analysts were modeling only about 2.5 percent annual revenue growth and continued losses to 2029, so you may find their far more cautious view on pricing pressure and mRNA demand useful to compare with your own expectations.

Explore 5 other fair value estimates on Moderna - why the stock might be worth 37% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 43 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.